Procter & Gamble Health shares soared 19% to touch an intraday high of ₹6,700 apiece on Wednesday, May 27, following the company's strong March quarter earnings announcement. According to reports from The Economic Times, the stock was trading at ₹6,295 apiece on the National Stock Exchange, representing an 11.37% surge as of 10:59 AM. The shares are currently just 0.58% below their 52-week high of ₹6,739, which was achieved on August 29, 2025. However, shares closed at ₹5,652.50 on Tuesday, May 26, falling 1.28% despite the strong quarterly results.
The Mumbai-based company delivered exceptional financial results for the fourth quarter of fiscal year 2025-26. As reported by The Economic Times, consolidated net profit jumped 54% to ₹94.6 crore in Q4 FY26 compared to ₹61.2 crore in the same period of the previous fiscal year. Revenue from operations increased 19% year-on-year to ₹370 crore in the January to March quarter, up from ₹311 crore in Q4 FY25. The company's operating profit (EBITDA) surged 67% to ₹135 crore as against ₹81 crore in the corresponding period last year, with EBITDA margin expanding dramatically to 36.60% compared to 26.02% in the year-ago period. The growth in profit was led by superior brand-building activities and supported by strengthened supply chain and go-to-market capabilities.
According to The Economic Times, P&G Health closed the 12-month financial year with reported sales of ₹1,385 crore and profit after tax of ₹327 crore, reflecting growth of 16% and 30% respectively compared with the corresponding 12-month period from April 2024 to March 2025. During the quarter, the company delivered sales of ₹365 crore, up 20% compared to last year, driven by strong brand fundamentals and positive consumer response to new innovations. The company's business continues to grow on the back of a strong pipeline of product innovations with a consumer-centric approach.
The board of directors of P&G Health recommended a dividend of ₹45 per equity share (face value of ₹10 each) for the financial year ended March 31, 2026. As reported by The Economic Times, the proposal is subject to approval by shareholders at the ensuing Annual General Meeting (AGM). If approved, the dividend will be paid on or before September 25, 2026. The company has a market capitalisation of ₹10,475.87 crore. The total dividend for FY26 amounts to ₹205 per share, consisting of a ₹160 interim dividend and the newly recommended final dividend of ₹45 per share. This high dividend payout reinforces the company's shareholder-friendly capital allocation policy.
According to The Economic Times, P&G Health highlighted key product launches including Livogen Iron Gummies, an easy-to-consume format for iron supplementation, and Neurobion Nerve Pain Relief Cream, a topical solution aimed at providing symptomatic relief from nerve-related pain. The company continued to drive community impact through its corporate social responsibility initiative, P&G Sehat, which focuses on improving healthcare access and awareness in underserved communities across the country. The company moved its year-end to March 31 from June 30, and in March 2026, PGHL partnered with the IMA to launch India's first guidelines on the clinical application of micronutrients in recovery. Tushar Gupta took over as Head of the Health Care division in January 2026, focusing on brand building and consumer innovation.
